Top

Published in:

09-06-2023 | Ibuprofen | Original Research Article

A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1–6 Months of Age

Authors: Chris D. Glover, John W. Berkenbosch, Mary B. Taylor, Nihar V. Patel, Byron Kaelin, Breanne H. Y. Gibson, John Zhong

Published in: Pediatric Drugs | Issue 5/2023

Abstract

Background

Enteral ibuprofen was first approved as a prescription drug in 1974 for the US market. An intravenous (IV) ibuprofen formulation is approved for use in children older than 6 months of age, but there are limited studies specifically evaluating the pharmacokinetics and safety in children 1–6 months of age.

Aims

The primary purpose of this study was to evaluate the pharmacokinetics of IV ibuprofen in infants younger than 6 months of age. The secondary objective was to evaluate the safety of single and repeated doses of IV ibuprofen in infants younger than 6 months of age.

Methods

This was an industry-sponsored multi-center study. Institutional Review Board approval and informed parental consent were obtained prior to enrollment. Hospitalized neonates and infants younger than 6 months of age with fever or expected postoperative pain were eligible. Enrolled patients received 10 mg/kg of IV ibuprofen every 6 h, with up to four doses per day. Patients were randomized to two sparse sampling technique pharmacokinetic sample time groups. Group 1 samples were drawn at 0, 30 min, and 2 h, while group 2 samples were drawn at 0 min, 1, and 4 h after administration.

Results

A total of 24 children were enrolled in the study, with 15 male patients and 9 female patients. The median age of the cohort was 4.4 months (range 1.1–5.9 months), and the median weight was 5.9 kg (range 2.3–8.8 kg). The arithmetic mean and standard error for peak plasma ibuprofen concentration was 56.28 ± 2.77 µg/mL. Plasma levels declined rapidly with a mean elimination half-life of 1.30 h. Time to peak ibuprofen effect and concentration were similar when compared with older pediatric patients. Clearance and volume of distribution were also similar to those reported in older pediatric patients. No drug-related adverse events were reported.

Conclusions

The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1–6 months of age are comparable to those in children older than 6 months of age.

Trial Registration

Clinicaltrials.gov Trial Registration number and date: NCT02583399—Registered July 2017.

Available only for authorised users

Rainsford KD. History and development of ibuprofen. In: Ibuprofen: discovery, development and therapeutics. New York: Wiley Blackwell; 2015. p. 1–21. https://doi.org/10.1002/9781118743614.ch1.CrossRef

Mencía S, Alonso C, Pallás-Alonso C, López-Herce J. Evaluation and treatment of pain in fetuses, neonates and children. Children. 2022. https://doi.org/10.3390/children9111688.CrossRefPubMedPubMedCentral

Doria M, Careddu D, Iorio R, Verrotti A, Chiappini E, Barbero GM, et al. Paracetamol and ibuprofen in the treatment of fever and acute mild–moderate pain in children: Italian experts’ consensus statements. Children. 2021. https://doi.org/10.3390/children8100873.CrossRefPubMedPubMedCentral

Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44(3):489–506. https://doi.org/10.1345/aph.1M332.CrossRefPubMed

Tan E, Braithwaite I, Mckinlay CJD, Dalziel SR. Comparison of acetaminophen (paracetamol) with ibuprofen for treatment of fever or pain in children younger than 2 years: a systematic review and meta-analysis. JAMA Netw Open. 2020. https://doi.org/10.1001/jamanetworkopen.2020.22398.CrossRefPubMedPubMedCentral

Pavliv L, Voss B, Rock A. Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. Am J Health-Syst Pharm. 2011;68(1):47–51. https://doi.org/10.2146/ajhp100120.CrossRefPubMed

Vilenchik R, Berkovitch M, Jossifoff A, Ben-Zvi Z, Kozer E. Oral versus rectal ibuprofen in healthy volunteers. J Popul Ther Clin Pharmacol. 2012;19(2):179–86.

Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther. 1999;65(6):653–60. https://doi.org/10.1016/S0009-9236(99)90087-5.CrossRefPubMed

Smith HS, Voss B. Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever. Drugs. 2012;72(3):327–37. https://doi.org/10.2165/11599230-000000000-00000.CrossRefPubMed

10.

Southworth S, Peters J, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther. 2009;31(9):1922–35. https://doi.org/10.1016/j.clinthera.2009.08.026.CrossRefPubMed

11.

Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children. Pediatr Drugs. 2001;3(11):817–58. https://doi.org/10.2165/00128072-200103110-00004.CrossRef

12.

Bookstaver B, Miller, Norris, Rudisill. Intravenous ibuprofen: the first injectable product for the treatment of pain and fever. J Pain Res. 2010;3:67–79. https://doi.org/10.2147/jpr.s6993.CrossRefPubMedPubMedCentral

13.

Capparelli EV. Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous ibuprofen lysine. J Pediatr Pharmacol Ther. 2007;12(3):158–70. https://doi.org/10.5863/1551-6776-12.3.158.CrossRefPubMedPubMedCentral

14.

Fields E. Summary review for regulatory action. Deputy Division Director Summary Review. NDA 22348 Supplement 005. Caldolor pediatric indication [Internet]. 2015 [cited 2023 May 2]. Available from: https://fda.report/media/95403/22348-Ibuprofen-DD-Clinical-PREA.pdf

15.

Caldolor [package insert]. Nashville: Cumberland Pharmaceuticals Inc.; 2021.

16.

Southworth SR, Sellers JA. Narrative summary of recently published literature on intravenous ibuprofen. Clin Ther. 2020;42:1210–21. https://doi.org/10.1016/j.clinthera.2020.05.004.CrossRefPubMed

17.

Khalil SN, Hahn BJ, Chumpitazi CE, Rock AD, Kaelin BA, Macias CG. A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. BMC Pediatr. 2017;17(1):42. https://doi.org/10.1186/s12887-017-0795-y.CrossRefPubMedPubMedCentral

18.

Lovecchio F, Premkumar A, Stepan JG, Albert TJ. fighting back: institutional strategies to combat the opioid epidemic: a systematic review. HSS J. 2019;15(1):66–71. https://doi.org/10.1007/s11420-018-09662-y.CrossRefPubMedPubMedCentral

19.

Cui X, Zhang J, Gao Z, Sun L, Zhang F. A randomized, double-blinded, placebo-controlled, single dose analgesic study of preoperative intravenous ibuprofen for tonsillectomy in children. Front Pediatr. 2022. https://doi.org/10.3389/fped.2022.956660.CrossRefPubMedPubMedCentral

20.

Patel NK, Shah SJ, Lee NK, Gao Q, Carullo VP, Yang CJ. Intraoperative intravenous ibuprofen use is not associated with increased post-tonsillectomy bleeding. Int J Pediatr Otorhinolaryngol. 2020. https://doi.org/10.1016/j.ijporl.2020.109965.CrossRefPubMedPubMedCentral

21.

Abdelbaser I, Abo-Zeid M, Hayes S, Taman HI. The analgesic effects of the addition of intravenous ibuprofen to a multimodal analgesia regimen for pain management after pediatric cardiac surgery: a randomized controlled study. J Cardiothorac Vasc Anesth. 2022. https://doi.org/10.1053/j.jvca.2022.11.016.CrossRefPubMed

22.

Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011;158(4):549-554.e1. https://doi.org/10.1016/j.jpeds.2010.10.008.CrossRefPubMed

23.

Aranda JV, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. Semin Perinatol. 2006;30:114–20. https://doi.org/10.1053/j.semperi.2006.04.003.CrossRefPubMed

24.

Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD003481.pub8.CrossRefPubMedPubMedCentral

25.

US Department of Health and Human Services. Guidance for industry bioanalytical method validation. [Internet]. 2018 [cited 2023 Jan 30]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf.

26.

Kozlowski LJ, Kost-Byerly S, Colantuoni E, Thompson CB, Vasquenza KJ, Rothman SK, et al. Pain prevalence, intensity, assessment and management in a hospitalized pediatric population. Pain Manag Nurs. 2014;15(1):22–35. https://doi.org/10.1016/j.pmn.2012.04.003.CrossRefPubMed

27.

Poddighe D, Brambilla I, Licari A, Marseglia GL. Ibuprofen for pain control in children new value for an old molecule [Internet]. 2018. Available from: http://www.pec-online.com.

28.

Walsh P, Rothenberg SJ, Bang H. Safety of ibuprofen in infants younger than six months: a retrospective cohort study. PLoS ONE. 2018;13(6): e0199493. https://doi.org/10.1371/journal.pone.0199493.CrossRefPubMedPubMedCentral

29.

Ziesenitz VC, Welzel T, van Dyk M, Saur P, Gorenflo M, van den Anker JN. Efficacy and safety of NSAIDs in infants: a comprehensive review of the literature of the past 20 years. Pediatr Drugs. 2022;24:603–55. https://doi.org/10.1007/s40272-022-00514-1.CrossRef

30.

Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992;121(6):969–73. https://doi.org/10.1016/s0022-3476(05)80354-3.CrossRefPubMed

31.

Morris PE, Promes JT, Guntupalli KK, Wright PE, Arons MM. A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. Crit Care. 2010. https://doi.org/10.1186/cc9089.CrossRefPubMedPubMedCentral

32.

Aranda J, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlou H, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86(3):289–93. https://doi.org/10.1111/j.1651-2227.1997.tb08892.x.CrossRefPubMed

33.

Van Overmeire B, Touw D, Schepens PJC, Kearns GL, Van Den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther. 2001;70(4):336–43.CrossRefPubMed

34.

Nahata MC, Durrell DE, Powell DA, Gupta N. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol. 1991. https://doi.org/10.1007/BF00265858.CrossRefPubMed

35.

Edison PE, Chen S, Yeo CL, Allen JC, Poon WB, Baral VR, et al. Pharmacokinetics of oral versus intravenous ibuprofen for closure of patent ductus arteriosus: a pilot randomised controlled study. J Paediatr Child Health. 2022;58(3):397–403. https://doi.org/10.1111/jpc.15720.CrossRefPubMed

36.

Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118(2):250–67. https://doi.org/10.1016/j.pharmthera.2008.02.005.CrossRefPubMed

37.

Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: Noninvasive assessment of body composition and growth. J Pediatr. 1986;109(4):698–707. https://doi.org/10.1016/s0022-3476(86)80245-1.CrossRefPubMed

Title: A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1–6 Months of Age
Authors: Chris D. Glover
John W. Berkenbosch
Mary B. Taylor
Nihar V. Patel
Byron Kaelin
Breanne H. Y. Gibson
John Zhong
Publication date: 09-06-2023
Publisher: Springer International Publishing
Keywords: Ibuprofen
Pharmacokinetics
Published in: Pediatric Drugs / Issue 5/2023
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-023-00576-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1–6 Months of Age

Abstract

Background

Aims

Methods

Results

Conclusions

Trial Registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusions

Trial Registration

Please log in to get access to this content

Other articles of this Issue 5/2023

Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review

Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature

20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval

A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants

Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series

Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review